down arrow

Regencell Bioscience Holdings Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: KYG7487R1002
USD
16.24
0.24 (1.5%)

Dec 05

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

15.0117.00

52 Week

0.0983.60
Valuation
Technical
Day's Volume

CASH

118.95 k

Shareholding (Jun 2024)

FII

0.00%

Held by 1 FIIs

DII

99.95%

Held by 0 DIIs

Promoter

0.00%

How big is Regencell Bioscience Holdings Ltd.?

22-Jun-2025

As of Jun 18, Regencell Bioscience Holdings Ltd. has a market capitalization of 38,570.13, categorized as a Micro Cap, with net sales of 3.00 million and a net profit of -1.26 million over the latest four quarters. Shareholder's funds are valued at 8.22 million, and total assets amount to 8.44 million.

Market Cap: As of Jun 18, Regencell Bioscience Holdings Ltd. has a market capitalization of 38,570.13, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 3.00 million and a net profit of -1.26 million.<BR><BR>Balance Sheet Snapshot: As of Jun 24, the shareholder's funds are valued at 8.22 million, and total assets amount to 8.44 million.

Read More

What does Regencell Bioscience Holdings Ltd. do?

22-Jun-2025

Regencell Bioscience Holdings Ltd. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting zero net sales and profits. It has a market capitalization of approximately USD 38.57 million.

Overview:<BR>Regencell Bioscience Holdings Ltd. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Sep 2008) <BR>Most recent Net Profit: 0 Million (Quarterly Results - Sep 2008) <BR>Market-cap: USD 38,570.13 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.96 <BR>Return on Equity: -999,999.00% <BR>Price to Book: 4,692.97<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More

Is Regencell Bioscience Holdings Ltd. technically bullish or bearish?

25-Jun-2025

As of June 17, 2025, the market trend is mildly bullish, supported by daily moving averages and a bullish monthly KST, but tempered by mildly bearish weekly MACD and Bollinger Bands, indicating a cautious outlook.

As of 17 June 2025, the technical trend has changed from bullish to mildly bullish. The current technical stance is mildly bullish, driven primarily by the daily moving averages indicating mild bullishness and the monthly KST being bullish. However, the weekly MACD and Bollinger Bands suggest a mildly bearish outlook, which tempers the overall bullish sentiment. The Dow Theory shows a mixed picture with weekly mildly bearish and monthly mildly bullish signals. Overall, while there are bullish indicators present, the mixed signals indicate caution in the current market environment.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 6,641 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.96

stock-summary
Return on Equity

-999,999.00%

stock-summary
Price to Book

988.93

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Sep 2008)
Net Profit:
0 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
22.47%
0%
22.47%
6 Months
-1.25%
0%
-1.25%
1 Year
10777.43%
0%
10777.43%
2 Years
5777.67%
0%
5777.67%
3 Years
-45.72%
0%
-45.72%
4 Years
2858.64%
0%
2858.64%
5 Years
0%
0%
0.0%

Regencell Bioscience Holdings Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-212.79%
EBIT to Interest (avg)
-1.16
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
1.81%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.06%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1085.92
EV to EBIT
-4353.72
EV to EBITDA
-5389.89
EV to Capital Employed
8916.97
EV to Sales
2972.83
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-204.81%
ROE (Latest)
-15.37%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 1 Schemes (0.05%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'08 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2008 is -61.54% vs 333.33% in Sep 2007",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2008 is 0.00% vs 0.00% in Sep 2007",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'08",
        "Sep'07",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.50",
          "val2": "1.30",
          "chgp": "-61.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.30",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.20",
          "val2": "-0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2023 is 0.00% vs 0.00% in Jun 2022",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2023 is 19.74% vs -484.62% in Jun 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'23",
        "Jun'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.50",
          "val2": "-7.00",
          "chgp": "21.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.10",
          "val2": "-7.60",
          "chgp": "19.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'08 - YoYstock-summary
Sep'08
Sep'07
Change(%)
Net Sales
0.50
1.30
-61.54%
Operating Profit (PBDIT) excl Other Income
-0.30
-0.00
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.20
-0.20
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Sep 2008 is -61.54% vs 333.33% in Sep 2007

Consolidated Net Profit

YoY Growth in quarter ended Sep 2008 is 0.00% vs 0.00% in Sep 2007

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Jun'23stock-summary
Jun'23
Jun'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-5.50
-7.00
21.43%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-6.10
-7.60
19.74%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Jun 2023 is 0.00% vs 0.00% in Jun 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jun 2023 is 19.74% vs -484.62% in Jun 2022

All Annual Resultsstock-summary
stock-summaryCompany CV
About Regencell Bioscience Holdings Ltd. stock-summary
stock-summary
Regencell Bioscience Holdings Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."